Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SOUTH PLAINFIELD, N.J., Nov. 01, 2016 -- Molecular Diagnostics company, Admera Health, (www.admerahealth.com) announced today that it received New York State Clinical Laboratory Evaluation Program (CLEP) approval for its 25 gene PGxOne™ Plus pharmacogenomics (PGx) test.
“This approval is a major milestone for Admera and exemplifies our aptitude to deliver molecular diagnostics that meet the highest quality standards,” said Guanghui Hu, PhD, President and CEO of Admera Health. “We are pleased to be able to offer New York residents clinical PGx testing. Results can guide effective treatment decisions, potentially reducing adverse drug events and trial-and-error drug selection and dosing. Furthermore, our report provides valuable information about harmful drug-drug, drug-food, drug-alcohol and drug-laboratory test interactions.”
PGxOne™ Plus leverages Next Generation Sequencing (NGS) technology to interrogate 25 genes with associated PGx information. Test results help predict how patients will respond to drug therapy for several therapeutic areas including, but not limited to, cardiology, psychiatry, pain management, and oncology. Examples of recommendations provided in the report are: consider alternatives when specific drugs should be avoided, adjust dose, use with caution, or normal response expected.
Recently, Admera updated the PGxOne™ Plus panel to include an additional 25 genes, bringing the number of drugs whose metabolism is affected to over 220.
Dr. Hu went on to elaborate, “This is our first step in providing NGS-based molecular diagnostics solutions in New York. We are forging ahead with plans to have our recently updated 50 gene PGxOne™ Plus panel available there, making it available in all 50 states.”
In addition to PGx testing, Admera Health offers clinical testing for the risk assessment and diagnosis of inherited cardiovascular diseases and cancer tumor profiling to guide selection of targeted therapies.
About Admera Health
Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.
Admera Health Contact: Brady Millican, VP Business Development 908-222-0533 [email protected]
